Corporate Overview & Integrated Report Statutory Reports Financial Statements

003

About Cipla1

Established in 1935, Cipla is a global pharmaceutical company focused on agile

and sustainable growth with a firm commitment to make medicines accessible and
available to those in need.
Our product portfolio spans complex generics as well as drugs in the respiratory,
anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key
therapeutic segments. With a rich portfolio, we are deepening our presence in
the home markets of India, as well as South Africa, North America, and other key
regulated and emerging markets. Our 47 manufacturing sites around the world
produce 50+ dosage forms and 1,500+ products using cutting-edge technology
platforms to cater to our 86 markets2 .

For over eight decades, making a
difference to patients has inspired every
aspect of Cipla’s work. Our paradigm-
changing offer of a triple anti-retroviral
therapy in HIV/AIDS at less than a
dollar a day in Africa in 2001 is widely
acknowledged as having contributed to
bringing inclusiveness, accessibility and
affordability to the centre of the
HIV movement.
Cipla is the third-largest
pharmaceutical Company
in India and the third
largest in the private
pharmaceutical market of
South Africa (IQVIA,
March 2022).
We are the second
largest Indian exporter
to emerging markets 3
and also among the most
dispensed generic players
in the US. Our approach to
responsible resource consumption,
efforts to enhance access and
affordability of medicines worldwide
and strong financial growth, provide a
robust foundation to build a responsible
business and stay committed to
sustainable growth.
By 2025, Cipla endeavours
to be a carbon neutral,
water neutral and zero
waste to landfill Company.
Cipla also aims to attain
AMR stewardship, green
chemistry and making
it right and ensure well-
being of employees and
partners.
As a responsible corporate citizen,
Cipla’s humanitarian approach to
healthcare in pursuit of its purpose
of ‘Caring for Life’ and deep-rooted
community linkages to wherever it is
present, makes it a partner of choice to
global health bodies, peers and
all stakeholders.
For more, please visit
www.cipla.com or click on
Twitter, Facebook and
LinkedIn channels.

1
GRI 102-1, GRI 102-2 , GRI 102-5, GRI 102-6, GRI 102-12
2
Represents countries / markets where sales are more than USD 0.5 million
3
EXIM Intellimax data for Emerging Markets (ex SAGA, CIS, China) for FY 2021-22